Bayer AG N

Bayer operates globally through Pharmaceuticals, Consumer Health, and Crop Science segments. Pharmaceuticals offers prescription products, specialty therapeutics, diagnostic imaging equipment, and cell/gene therapy. Consumer Health markets nonprescription medicines for self-medication and self-care, as well as seeds and seed dressing. The company collaborates with various organizations, including Acuitas Therapeutics, Peking University, Swiss Tropical and Public Health Institute, bit.bio Ltd., Hologic, Inc., Twist Bioscience Corporation, and CrossBay Medical Inc. Products are distributed through wholesalers, pharmacies, supermarkets, online retailers, hospitals, and directly to farmers.

Overview

Sector

Pharmaceutical

Target Price

0.0 EUR

Current Price

27.0 EUR

Potential

-100%

Strengths

Price to book ratio (0.83) is lower than the sector mean (8.32).
EV/EBITDA (6.66) is lower than the sector mean (21.51).
Price to free cash flow (5.77) is lower than the sector mean.

Weaknesses

With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
Analysts expect revenues to decline in the coming year.
The company has high debt. Net Debt to EBITDA Ratio (3.71) is higher than the sector mean.
The company have lower returns than the sector in which it operates. ROIC (10.33%) is significantly lower than the sector mean (16.32%).
EV/EBIT (2489.95) is significantly higher than the sector mean.

Key Financial Data

Indicator	Value
PER	100.0
EV/EBITDA	6.7
Price/Free Cash Flow'	5.8
ROIC	10.3%
Net Debt/EBITDA	3.7